Your session is about to expire
← Back to Search
Unknown
ADX-629 for Chronic Cough
Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 - 14 of each treatment period
Summary
This trial tests ADX-629, an oral medication, on patients with chronic cough that doesn't respond to usual treatments or has no known cause. It aims to see if the medication can safely and effectively reduce their coughing symptoms.
Eligible Conditions
- Chronic Cough
- Chronic Bronchitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to the end of each 14-day treatment period (day 1 - 14 of each treatment period)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to the end of each 14-day treatment period (day 1 - 14 of each treatment period)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events (AEs)
Secondary study objectives
Change from baseline in awake cough frequency after 2-week treatment period
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ADX-629Experimental Treatment1 Intervention
Subjects will be randomized to receive ADX-629 300mg tablets administered orally twice a day for 14 days.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will be randomized to receive matching placebo tablets administered orally twice a day for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-629
2021
Completed Phase 2
~110
Find a Location
Who is running the clinical trial?
Aldeyra Therapeutics, Inc.Lead Sponsor
32 Previous Clinical Trials
4,619 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger